HOWL Logo

Werewolf Therapeutics, Inc. (HOWL) 

NASDAQ$1.2
Market Cap
$53.48M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
619 of 924
Rank in Industry
356 of 527

HOWL Insider Trading Activity

HOWL Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$00–
Sells
$00–

Related Transactions

No records found

About Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a â€¦

Insider Activity of Werewolf Therapeutics, Inc.

Over the last 12 months, insiders at Werewolf Therapeutics, Inc. have bought $0 and sold $0 worth of Werewolf Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Werewolf Therapeutics, Inc. have bought $50.56M and sold $40,242 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,853,000 shares for transaction amount of $4.1M was made by RA CAPITAL MANAGEMENT, L.P. (director) on 2023‑01‑06.

List of Insider Buy and Sell Transactions, Werewolf Therapeutics, Inc.

2023-01-06PurchaseRA CAPITAL MANAGEMENT, L.P.director
1.85M
5.9218%
$2.21$4.1M+17.78%
2021-12-15SaleLeonard ReidChief Operating Officer
3,000
0.0157%
$13.41$40,242-65.47%
2021-06-16PurchaseRA CAPITAL MANAGEMENT, L.P.
9,285
0.0512%
$13.37$124,140+0.29%
2021-06-15PurchaseRA CAPITAL MANAGEMENT, L.P.
7,958
0.0452%
$12.95$103,056+6.61%
2021-06-14PurchaseRA CAPITAL MANAGEMENT, L.P.
306,055
1.727%
$12.75$3.9M+7.62%
2021-05-04PurchaseGADICKE ANSBERT10 percent owner
245,000
1.3777%
$16.00$3.92M-12.48%
2021-05-04PurchaseEVNIN LUKE
150,799
0.848%
$16.00$2.41M-12.48%
2021-05-04PurchaseRA CAPITAL MANAGEMENT, L.P.
1.72M
9.6439%
$16.00$27.44M-12.48%
2021-05-04PurchaseMPM BioVentures 2014, L.P.10 percent owner
125,759
0.7072%
$16.00$2.01M-12.48%
2021-05-04PurchaseFlynn James E10 percent owner
800,000
4.4986%
$16.00$12.8M-12.48%
2021-05-04PurchaseTaiho Ventures LLC10 percent owner
312,500
1.7573%
$16.00$5M-12.48%
2021-05-04PurchaseAsanuma Sakae
312,500
1.7573%
$16.00$5M-12.48%
2021-05-04PurchaseLazarus Alon
400,000
2.2493%
$16.00$6.4M-12.48%
2021-05-04PurchaseArkin Bio Ventures 2 L.P.10 percent owner
400,000
2.2493%
$16.00$6.4M-12.48%
2021-05-04PurchaseLongwood Fund III GP, LLC10 percent owner
250,000
1.4058%
$16.00$4M-12.48%
2021-05-04PurchaseSphera Global Healthcare Management LP10 percent owner
475,000
2.671%
$16.00$7.6M-12.48%
2020-12-23PurchaseEVNIN LUKE
15.88M
–
$0$0+1097.36%
2020-12-23PurchaseAsanuma Sakae
7.6M
–
$0.46$3.5M+1097.36%
2020-12-23PurchaseLazarus Alon
7.12M
–
$8.00$56.97M+1097.36%
Total: 19
*Some uncertain data for Preferred Stock share type transactions are shown in italics; for actual data please follow the link

Insider Historical Profitability

<0.0001%
GADICKE ANSBERT10 percent owner
6672183
14.9724%
$8.01M10<0.0001%
RA CAPITAL MANAGEMENT, L.P.director
5701056
12.7932%
$6.84M50+3.97%
EVNIN LUKE
4284172
9.6137%
$5.14M20<0.0001%
MPM BioVentures 2014, L.P.10 percent owner
3187998
7.1539%
$3.83M10<0.0001%
Flynn James E10 percent owner
2552787
5.7285%
$3.06M10<0.0001%

Historical Insider Profitability vs. Competitors

$459,011,221
33
33.04%
$57.94M
$18,274,594
22
-26.07%
$49.68M
$167,476,357
20
-1.54%
$50.65M
$26,736,140
20
-18.64%
$54.85M
$20,234,041
17
2.08%
$56.81M

HOWL Institutional Investors: Active Positions

Increased Positions40+66.67%550,969+1.71%
Decreased Positions21-35%5M-14.25%
New Positions11New146,564New
Sold Out Positions8Sold Out3MSold Out
Total Postitions79+31.67%28M-12.54%

HOWL Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Ra Capital Management, L.P.$7,620.0013.66%6.14M00%2024-12-31
Mpm Asset Management Llc$5,312.009.52%4.28M00%2024-12-31
Pfm Health Sciences, Lp$3,603.006.46%2.91M-493,282-14.51%2024-12-31
Mpm Bioimpact Llc$2,961.005.31%2.39M00%2024-12-31
Bank Of America Corp /De/$2,578.004.62%2.08M-74,842-3.48%2024-12-31
Blackrock, Inc.$2,109.003.78%1.7M+63,382+3.87%2024-12-31
Vanguard Group Inc$1,762.003.16%1.42M+5,439+0.38%2024-12-31
Rubric Capital Management Lp$1,654.002.96%1.33M00%2024-12-31
Geode Capital Management, Llc$871.001.56%702,558+16,569+2.42%2024-12-31
Sphera Funds Management Ltd.$777.001.39%626,81000%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.